MCID: UTR043
MIFTS: 40

Uterine Sarcoma

Categories: Cancer diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Uterine Sarcoma

MalaCards integrated aliases for Uterine Sarcoma:

Name: Uterine Sarcoma 20 54 17
Uterine Corpus Sarcoma 70
Sarcoma of the Uterus 20

Classifications:



External Ids:

UMLS 70 C0338113

Summaries for Uterine Sarcoma

MalaCards based summary : Uterine Sarcoma, also known as uterine corpus sarcoma, is related to rhabdomyosarcoma and gastrointestinal stromal tumor. An important gene associated with Uterine Sarcoma is ABCB1 (ATP Binding Cassette Subfamily B Member 1), and among its related pathways/superpathways are Gastric cancer and MicroRNAs in cancer. The drugs Ifosfamide and Gemcitabine have been mentioned in the context of this disorder. Affiliated tissues include uterus, smooth muscle and cervix, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 73 The uterine sarcomas form a group of malignant tumors that arises from the smooth muscle or connective... more...

Related Diseases for Uterine Sarcoma

Diseases related to Uterine Sarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 125)
# Related Disease Score Top Affiliating Genes
1 rhabdomyosarcoma 29.4 SMARCB1 CCND2 ABCC1 ABCB1
2 gastrointestinal stromal tumor 29.0 SMARCB1 CDK2 ABCB1
3 sarcoma 11.1
4 spindle cell sarcoma 11.1
5 leiomyosarcoma 10.9
6 endometrial stromal sarcoma 10.8
7 leiomyoma 10.6
8 carcinosarcoma 10.6
9 adenosarcoma 10.4
10 myeloid sarcoma 10.4
11 myoma 10.4
12 leiomyoma, uterine 10.4
13 myofibroma 10.4
14 uterine inversion 10.3
15 soft tissue sarcoma 10.3
16 endometrial cancer 10.2
17 alveolar soft part sarcoma 10.2
18 ewing sarcoma 10.2
19 embryonal sarcoma 10.2
20 rare tumor 10.2
21 reticulum cell sarcoma 10.1
22 myelodysplastic syndrome 10.1
23 neutropenia 10.1
24 fibrosarcoma 10.1
25 sarcomatosis 10.1
26 small cell carcinoma 10.0
27 adenocarcinoma 10.0
28 mesenchymal cell neoplasm 10.0
29 vaginal discharge 10.0
30 uterine carcinosarcoma 10.0
31 ovarian small cell carcinoma 10.0
32 temporal lobe neoplasm 10.0 ABCC1 ABCB1
33 colchicine resistance 10.0 ABCC1 ABCB1
34 microsporidiosis 10.0 ABCC1 ABCB1
35 cholangiolocellular carcinoma 10.0 ABCC1 ABCB1
36 familial episodic pain syndrome 10.0 ABCC1 ABCB1
37 congenital heart defects, hamartomas of tongue, and polysyndactyly 10.0
38 sarcoma, synovial 10.0
39 lymphangioleiomyomatosis 10.0
40 lung cancer susceptibility 3 10.0
41 fibroma 10.0
42 squamous cell carcinoma 10.0
43 mast-cell sarcoma 10.0
44 uterine corpus sarcoma 10.0
45 chromosomal triplication 10.0
46 splenomegaly 10.0
47 rare gynecological tumor 10.0
48 hemangiopericytoma, malignant 9.9
49 adenomyosis 9.9
50 cervical cancer 9.9

Graphical network of the top 20 diseases related to Uterine Sarcoma:



Diseases related to Uterine Sarcoma

Symptoms & Phenotypes for Uterine Sarcoma

GenomeRNAi Phenotypes related to Uterine Sarcoma according to GeneCards Suite gene sharing:

26 (show all 11)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00107-A-1 9.47 DCK
2 Decreased viability GR00221-A-1 9.47 DCK SMARCB1
3 Decreased viability GR00221-A-2 9.47 CDK2 DCK SMARCB1
4 Decreased viability GR00221-A-3 9.47 CDK2 SMARCB1
5 Decreased viability GR00221-A-4 9.47 DCK
6 Decreased viability GR00240-S-1 9.47 DCK
7 Decreased viability GR00249-S 9.47 SMARCB1
8 Decreased viability GR00301-A 9.47 CDK2
9 Decreased viability GR00381-A-1 9.47 SMARCB1
10 Decreased viability GR00386-A-1 9.47 DCK
11 Decreased cell proliferation GR00353-A 8.96 CDK2 DCK

MGI Mouse Phenotypes related to Uterine Sarcoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.63 ABCB1 ABCC1 CCND2 CDK2 DCK SMARCB1
2 immune system MP:0005387 9.43 ABCB1 ABCC1 CCND2 CDK2 DCK SMARCB1
3 liver/biliary system MP:0005370 8.92 ABCB1 CCND2 CDK2 SMARCB1

Drugs & Therapeutics for Uterine Sarcoma

Drugs for Uterine Sarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 74)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ifosfamide Approved Phase 3 3778-73-2 3690
2
Gemcitabine Approved Phase 3 95058-81-4 60750
3
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
4
Sargramostim Approved, Investigational Phase 3 123774-72-1, 83869-56-1
5
Bevacizumab Approved, Investigational Phase 3 216974-75-3
6
Lenograstim Approved, Investigational Phase 3 135968-09-1
7
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
8
Dehydroepiandrosterone Approved, Investigational, Nutraceutical Phase 3 53-43-0 5881
9
Molgramostim Investigational Phase 3 99283-10-0
10
Isophosphamide mustard Phase 3 100427
11 DHEA (Dehydroepiandrosterone) Phase 3
12 Adjuvants, Immunologic Phase 3
13 Immunologic Factors Phase 3
14 Tubulin Modulators Phase 3
15 Immunosuppressive Agents Phase 3
16 Antimitotic Agents Phase 3
17 Antiviral Agents Phase 3
18 Anti-Infective Agents Phase 3
19 Antimetabolites Phase 3
20 Angiogenesis Inhibitors Phase 3
21 Antineoplastic Agents, Immunological Phase 3
22 Immunoglobulins Phase 3
23 Mitogens Phase 3
24 Immunoglobulin G Phase 3
25 Endothelial Growth Factors Phase 3
26 Immunoglobulins, Intravenous Phase 3
27 Antibodies, Monoclonal Phase 3
28 Antibodies Phase 3
29 Anti-Bacterial Agents Phase 3
30 Antibiotics, Antitubercular Phase 3
31
Liposomal doxorubicin Phase 3 31703
32
Progesterone Approved, Vet_approved Phase 1, Phase 2 57-83-0 5994
33
Fondaparinux Approved, Investigational Phase 2 104993-28-4
34
Thalidomide Approved, Investigational, Withdrawn Phase 2 50-35-1 5426
35
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
36
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
37
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
38
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
39
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030
40
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
41
Vorinostat Approved, Investigational Phase 2 149647-78-9 5311
42
Onapristone Investigational Phase 1, Phase 2 96346-61-1
43 Hormone Antagonists Phase 1, Phase 2
44 Hormones Phase 1, Phase 2
45
protease inhibitors Phase 2
46 Fibrinolytic Agents Phase 2
47 Serine Proteinase Inhibitors Phase 2
48 Antithrombin III Phase 2
49 PENTA Phase 2
50 Antithrombins Phase 2

Interventional clinical trials:

(show all 33)
# Name Status NCT ID Phase Drugs
1 Phase III Study About the Effects of the Addition of Polychemotherapy to Adjuvant Radiotherapy in the Treatment of Non-Metastatic Uterine Sarcomas Unknown status NCT00162721 Phase 3 doxorubicin, ifosfamide, cisplatin
2 Vaginal DHEA for Vaginal Symptoms: A Phase III Randomized, Double Blind, Placebo- Controlled Trial Completed NCT01376349 Phase 3 prasterone
3 A Phase III Randomized Clinical Trial of Laparoscopic Pelvic and Para-Aortic Node Sampling With Vaginal Hysterectomy and BSO Versus Open Laparotomy With Pelvic and Para-Aortic Node Sampling and Abdominal Hysterectomy and BSO in Endometrial Adenocarcinoma and Uterine Sarcoma, Clinical Stage I, IIA, Grade I, II, III Completed NCT00002706 Phase 3
4 Phase III Randomized Study of Adjuvant Pelvic Radiotherapy Versus Observation Alone in Patients With Completely Resected, Stage I or II, High-Grade Uterine Sarcoma Completed NCT00002459 Phase 3
5 A Randomized Phase III Evaluation of Docetaxel (NSC #628503) and Gemcitabine (NSC #613327) Plus G-CSF With Bevacizumab (NSC #704865) Versus Docetaxel (NSC #628503) and Gemcitabine (NSC #613327) Plus G-CSF With Placebo in the Treatment of Recurrent or Advanced Leiomyosarcoma of the Uterus Terminated NCT01012297 Phase 3 Docetaxel;Gemcitabine Hydrochloride
6 A Phase III Randomized Trial of Gemcitabine (NSC# 613327) Plus Docetaxel (NSC# 628503) Followed by Doxorubicin (NSC# 123127) Versus Observation for Uterus-Limited, High Grade Uterine Leiomyosarcoma Terminated NCT01533207 Phase 3 Docetaxel;Doxorubicin Hydrochloride;Gemcitabine Hydrochloride
7 Phase 1-2 Study of Onapristone in Patients With Progesterone Receptor Expressing Cancers Unknown status NCT02052128 Phase 1, Phase 2 onapristone
8 Women's Cancer Center Protocol #45: Prolonged Venous Thromboembolism Prophylaxis With Fondaparinux in Gynecologic Oncology Patients: An Open Label Phase II Trial Completed NCT00381888 Phase 2 fondaparinux sodium
9 A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus Completed NCT01637961 Phase 2 Alisertib
10 A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus Completed NCT01168232 Phase 2 Ixabepilone
11 A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus Completed NCT01247571 Phase 2 Pazopanib Hydrochloride
12 A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus Completed NCT01220609 Phase 2 Ixabepilone
13 A Phase II Evaluation of Thalidomide (NSC #66847) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus Completed NCT00025506 Phase 2 Thalidomide
14 A Phase II Evaluation of Thalidomide (NSC #66847) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus Completed NCT00025220 Phase 2 Thalidomide
15 A Phase II Evaluation of Gemcitabine (NSC #613327) and Docetaxel (NSC # 628503) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus Completed NCT00114218 Phase 2 Gemcitabine Hydrochloride;Docetaxel
16 A Phase II Evaluation of Docetaxel and Gemcitabine Plus G-CSF in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus Completed NCT00031629 Phase 2 Docetaxel;Gemcitabine Hydrochloride
17 A Phase II Evaluation of Sunitinib Malate (Sutent®, SU11248, NCI-Supplied Agent , NSC # 736511) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus Completed NCT00378911 Phase 2 sunitinib malate
18 A Phase II Study of BAY 43-9006 in Advanced/Recurrent Uterine Carcinoma/Carcinosarcoma Completed NCT00238121 Phase 2 sorafenib tosylate
19 A Phase II Evaluation of Gleevec(TM) (NCI-Supplied Agent: STI571 [Imatinib Mesylate], NSC# 716051) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus Completed NCT00075400 Phase 2 imatinib mesylate
20 A Randomized Double-blind Phase II Study Evaluating the Role of Maintenance Therapy With Cabozantinib in High Grade Undifferentiated Uterine Sarcoma (HGUS) After Stabilization or Response to Doxorubicin +/- Ifosfamide Following Surgery or in Metastatic First Line Treatment Recruiting NCT01979393 Phase 2 Cabozantinib;Placebo
21 Pilot Phase II Study of Temsirolimus in Patients With Recurrent Mixed Mesodermal and Mullerian Tumors (Carcinosarcoma) of the Uterus Terminated NCT01061606 Phase 2 temsirolimus
22 A Pilot Study of Peroral Vorinostat (SAHA) in Patients With Refractory Histone Deacetylase-positive Uterine Sarcoma Terminated NCT03509207 Phase 2 Vorinostat Oral Capsule
23 Evaluation of Mitomycin, Doxorubicin and Cisplatin in the Treatment of Recurrent or Advanced Uterine Sarcomas Terminated NCT00002993 Phase 2 cisplatin;doxorubicin hydrochloride;mitomycin C
24 Phase I Randomized Study of MAGE-12 Peptide Vaccine in Patients With Refractory Metastatic Cancer Expressing MAGE-12 Antigen Completed NCT00020267 Phase 1 interleukin-2;MAGE-12 peptide vaccine;Montanide ISA-51
25 Descriptive Study to Evaluate the Information and Psychosocial Issues on the Risk on Infertility in Cancer Patients After Receiving Treatment in a Comprehensive Cancer Center Unknown status NCT01295463
26 Northwestern Ovarian Cancer Early Detection & Prevention Program: A Specimen and Data Study Unknown status NCT00005095
27 A Randomized Controlled Trial to Investigate the Role of Low or High 'Fibre' Diets in Patients Undergoing Pelvic Radiotherapy - The Fibre Study Completed NCT01170299
28 A Pilot Study of Adjuvant Docetaxel Plus Gemcitabine in Patients With Completely Resected Leiomyosarcoma (LMS) of the Uterus Completed NCT00614835 Docetaxel plus Gemcitabine
29 The Rehabilitation Needs of People Who Have Had an Upper Gastrointestinal or a Gynecological Cancer Completed NCT01216813
30 Expanded Access to Everolimus, for an Individual Patient With Uterine Sarcoma (CTMS#18-0020) Available NCT03493165 Everolimus
31 Diagnostic Performances of Preoperative Echo-guided Uterine Biopsy in the Management of Suspect Uterine Sarcoma Tumors Not yet recruiting NCT04250766
32 A Pilot Trial of Radiation Therapy "Sandwiched" Between Paclitaxel and Carboplatin in Patients With Uterine Carcinosarcoma Terminated NCT01367301 paclitaxel;carboplatin
33 A Pilot Safety and Toxicity Trial of Adjuvant Chemotherapy With Gemcitabine and Docetaxel and Radiation Therapy for Completely Resected Uterine Leiomyosarcoma Terminated NCT01958580 Gemcitabine Hydrochloride;Docetaxel

Search NIH Clinical Center for Uterine Sarcoma

Genetic Tests for Uterine Sarcoma

Anatomical Context for Uterine Sarcoma

MalaCards organs/tissues related to Uterine Sarcoma:

40
Uterus, Smooth Muscle, Cervix, Myeloid, Ovary, Endothelial, Bone Marrow

Publications for Uterine Sarcoma

Articles related to Uterine Sarcoma:

(show top 50) (show all 991)
# Title Authors PMID Year
1
Modulation of multidrug resistance p-glycoprotein activity by flavonoids and honokiol in human doxorubicin- resistant sarcoma cells (MES-SA/DX-5): implications for natural sedatives as chemosensitizing agents in cancer therapy. 61 54
20487633 2010
2
Low frequency of somatic mutations in uterine sarcomas: a molecular analysis and review of the literature. 54 61
20122944 2010
3
Retention of the radiotracers 64Cu-ATSM and 64Cu-PTSM in human and murine tumors is influenced by MDR1 protein expression. 54 61
19617332 2009
4
Quinoline derivative KB3-1 potentiates paclitaxel induced cytotoxicity and cycle arrest via multidrug resistance reversal in MES-SA/DX5 cancer cells. 61 54
18845169 2008
5
Reversal of P-glycoprotein-mediated multidrug resistance in human sarcoma MES-SA/Dx-5 cells by nonsteroidal anti-inflammatory drugs. 61 54
18813811 2008
6
Effects of photoactivated 5-aminolevulinic acid hexyl ester on MDR1 over-expressing human uterine sarcoma cells. 54 61
18625294 2008
7
Distinct N-glycan glycosylation of P-glycoprotein isolated from the human uterine sarcoma cell line MES-SA/Dx5. 61 54
17692467 2007
8
PDGFR-alpha as a potential therapeutic target in uterine sarcomas. 61 54
17049587 2007
9
Prognostic factors and expression of p53 and mdm-2 in uterine sarcomas. 54 61
16930603 2006
10
Scintigraphic imaging of P-glycoprotein expression with a radiolabelled antibody. 61 54
16832635 2006
11
Stable suppression of MDR-1 gene using siRNA expression vector to reverse drug resistance in a human uterine sarcoma cell line. 54 61
15921732 2005
12
Lysosomal accumulation of drugs in drug-sensitive MES-SA but not multidrug-resistant MES-SA/Dx5 uterine sarcoma cells. 54 61
10867652 2000
13
Diffusion-tensor imaging for differentiating uterine sarcoma from degenerative uterine fibroids. 61
33358441 2021
14
ASO Author Reflections: Spotlight on Malignant Peritoneal Cytology in Uterine Sarcoma: A Potential Avenue for Future Research. 61
33105503 2021
15
An update of molecular findings in uterine tumor resembling ovarian sex cord tumor and GREB1-rearranged uterine sarcoma with variable sex-cord differentiation. 61
33099842 2021
16
Significance of Malignant Peritoneal Cytology on Survival of Women with Uterine Sarcoma. 61
33063261 2021
17
Differentiating uterine sarcoma from leiomyoma: BET1T2ER Check! 61
33684303 2021
18
SATB2 Expression in Uterine Sarcoma: A Multicenter Retrospective Study. 61
33720083 2021
19
Update on SWI/SNF-related gynecologic mesenchymal neoplasms: SMARCA4-deficient uterine sarcoma and SMARCB1-deficient vulvar neoplasms. 61
33252159 2021
20
Low-grade endometrial stromal sarcoma: A Turkish uterine sarcoma group study analyzing prognostic factors and disease outcomes. 61
33375988 2021
21
High-grade uterine sarcoma with osteosarcomatous differentiation arising from a MED12-mutated leiomyoma, a case report. 61
33444473 2021
22
NTRK and other recently described kinase fusion positive uterine sarcomas: A review of a group of rare neoplasms. 61
33099837 2021
23
Relationships between highly recurrent tumor suppressor alterations in 489 leiomyosarcomas. 61
33788262 2021
24
Uterine Sarcomas: A Retrospective Analysis of a Cohort of 62 Patients. 61
33747651 2021
25
Perioperative SARS-CoV-2 infection among women undergoing major gynecologic cancer surgery in the COVID-19 era: A nationwide, cohort study from Turkey. 61
33223221 2021
26
Annual report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology: Annual patient report for 2017 and annual treatment report for 2012. 61
33631867 2021
27
The incidence of unexpected gynaecological malignancies in hysterectomies carried out for benign indications. 61
33448228 2021
28
Prognostic factors and survival outcomes of women with uterine leiomyosarcoma: A Turkish Uterine Sarcoma Group Study-003. 61
33685725 2021
29
Uterine sarcoma with posterior reversible encephalopathy syndrome associated with pazopanib. 61
33044009 2021
30
S100 and Pan-Trk Staining to Report NTRK Fusion-Positive Uterine Sarcoma: Proceedings of the ISGyP Companion Society Session at the 2020 USCAP Annual Meeting. 61
33290352 2021
31
High-grade endometrial stromal sarcoma versus undifferentiated uterine sarcoma: a Turkish uterine sarcoma group study-001. 61
33392719 2021
32
Specificity of the lactate dehydrogenase isoenzyme index as a preoperative screen for uterine sarcoma before myomectomy. 61
33070962 2021
33
[Indirect causes of maternal deaths (except stroke, cardiovascular diseases and infections) in France 2013-2015]. 61
33161193 2021
34
The Landscape of Glycogen Synthase Kinase-3 Beta Genomic Alterations in Cancer. 61
33087512 2021
35
Diagnosis, treatment and survival of uterine sarcoma: A retrospective cohort study of 122 cases. 61
33093955 2020
36
Complex formation and cytotoxicity of Triapine derivatives: a comparative solution study on the effect of the chalcogen atom and NH-methylation. 61
33185224 2020
37
Undifferentiated and dedifferentiated neoplasms of the female genital tract. 61
33323288 2020
38
Italian consensus conference on management of uterine sarcomas on behalf of S.I.G.O. (Societa' italiana di Ginecologia E Ostetricia). 61
32992154 2020
39
COL1A1-PDGFB fusion uterine sarcoma and its response to Imatinib therapy. 61
33364286 2020
40
Survival outcomes and prognostic factors of endometrial stromal sarcoma and undifferentiated uterine sarcoma. 61
33210235 2020
41
Incidence of occult uterine sarcoma and other unexpected pathologies in patients having surgery for presumed myomas: A retrospective observational study. 61
33217603 2020
42
Does iatrogenic tumor rupture during surgery have prognostic implications for the outcome of uterine sarcomas? 61
32948637 2020
43
Phase 2 study of cetuximab (Erbitux) in patients with progressive or recurrent endometrial cancer. 61
33020204 2020
44
Bullous vesicant-type reaction to docetaxel along the venous tract: A case report. 61
33005719 2020
45
MRI to Differentiate Atypical Leiomyoma from Uterine Sarcoma. 61
32936067 2020
46
Endometrial stromal sarcoma: A review of rare mesenchymal uterine neoplasm. 61
32830415 2020
47
TMP3-NTRK1 rearranged uterine sarcoma: A case report. 61
32939344 2020
48
A randomized double-blind phase II study evaluating the role of maintenance therapy with cabozantinib in high-grade uterine sarcoma after stabilization or response to doxorubicin ± ifosfamide following surgery or in metastatic first line treatment (EORTC62113). 61
32546554 2020
49
Targeted RNA expression profiling identifies high-grade endometrial stromal sarcoma as a clinically relevant molecular subtype of uterine sarcoma. 61
33077922 2020
50
Angiosarcomas of Primary Gynecologic Origin - A Case Series and Review of the Literature. 61
32988901 2020

Variations for Uterine Sarcoma

Expression for Uterine Sarcoma

Search GEO for disease gene expression data for Uterine Sarcoma.

Pathways for Uterine Sarcoma

Pathways related to Uterine Sarcoma according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.4 SMARCB1 CDK2 ABCB1
2 12.1 CCND2 ABCC1 ABCB1
3
Show member pathways
11.63 ABCC1 ABCB1
4
Show member pathways
11.61 CDK2 CCND2
5 11.51 DCK CDK2
6
Show member pathways
11.44 CDK2 CCND2
7
Show member pathways
11.38 CDK2 CCND2
8
Show member pathways
11.31 ABCC1 ABCB1
9 11.27 SMARCB1 CDK2
10
Show member pathways
11.21 ABCC1 ABCB1
11 11.12 CDK2 CCND2
12
Show member pathways
11.06 ABCC1 ABCB1
13 10.91 CDK2 CCND2
14 10.73 ABCC1 ABCB1
15
Show member pathways
10.62 ABCC1 ABCB1
16 10.43 ABCC1 ABCB1
17 10.33 ABCC1 ABCB1
18 10.05 DCK ABCC1 ABCB1
19 9.96 ABCC1 ABCB1

GO Terms for Uterine Sarcoma

Cellular components related to Uterine Sarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cyclin-dependent protein kinase holoenzyme complex GO:0000307 8.62 CDK2 CCND2

Biological processes related to Uterine Sarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 phospholipid translocation GO:0045332 9.32 ABCC1 ABCB1
2 export across plasma membrane GO:0140115 9.26 ABCC1 ABCB1
3 transepithelial transport GO:0070633 9.16 ABCC1 ABCB1
4 carboxylic acid transmembrane transport GO:1905039 8.96 ABCC1 ABCB1
5 lactone transport GO:0042969 8.62 ABCC1 ABCB1

Molecular functions related to Uterine Sarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ATP binding GO:0005524 9.71 DCK CDK2 ABCC1 ABCB1
2 ATPase activity, coupled to transmembrane movement of substances GO:0042626 9.37 ABCC1 ABCB1
3 xenobiotic transmembrane transporter activity GO:0042910 9.32 ABCC1 ABCB1
4 efflux transmembrane transporter activity GO:0015562 9.26 ABCC1 ABCB1
5 xenobiotic transmembrane transporting ATPase activity GO:0008559 9.16 ABCC1 ABCB1
6 carboxylic acid transmembrane transporter activity GO:0046943 8.96 ABCC1 ABCB1
7 lactone transmembrane transporter activity GO:0042971 8.62 ABCC1 ABCB1

Sources for Uterine Sarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....